ONCOS-102: A Step Forward or Sideways?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 36269283.
- Also identified by DOI 10.1158/1078-0432.CCR-22-2887.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of anti-PD-1 refractory melanoma remains a challenge. Intratumoral injection of ONCOS-102, a chimeric oncolytic adenovirus expressing GMCSF, into anti-PD-1-resistant melanoma with administration of pembrolizumab was safe and effective. Response to therapy was associated with increased lymphocyte infiltration and expression of cytotoxicity and costimulatory genes. See related article by Shoushtari et al., p. 100.
Medical subject headings
- Oncolytic Virotherapy
- Melanoma